Literature DB >> 30111561

Exploring Crimean-Congo Hemorrhagic Fever Virus-Induced Hepatic Injury Using Antibody-Mediated Type I Interferon Blockade in Mice.

Michael E Lindquist1, Xiankun Zeng2, Louis A Altamura3, Sharon P Daye2, Korey L Delp3, Candace Blancett2, Kayla M Coffin2, Jeffrey W Koehler3, Susan Coyne3, Charles J Shoemaker1, Aura R Garrison1, Joseph W Golden4.   

Abstract

Crimean-Congo hemorrhagic fever virus (CCHFV) can cause severe hepatic injury in humans. However, the mechanism(s) causing this damage is poorly characterized. CCHFV produces an acute disease, including liver damage, in mice lacking type I interferon (IFN-I) signaling due to either STAT-1 gene deletion or disruption of the IFN-I receptor 1 gene. Here, we explored CCHFV-induced liver pathogenesis in mice using an antibody to disrupt IFN-I signaling. When IFN-I blockade was induced within 24 h postexposure to CCHFV, mice developed severe disease with greater than 95% mortality by 6 days postexposure. In addition, we observed increased proinflammatory cytokines, chemoattractants, and liver enzymes in these mice. Extensive liver damage was evident by 4 days postexposure and was characterized by hepatocyte necrosis and the loss of CLEC4F-positive Kupffer cells. Similar experiments in CCHFV-exposed NOD-SCID-γ (NSG), Rag2-deficient, and perforin-deficient mice also demonstrated liver injury, suggesting that cytotoxic immune cells are dispensable for hepatic damage. Some apoptotic liver cells contained viral RNA, while other apoptotic liver cells were negative, suggesting that cell death occurred by both intrinsic and extrinsic mechanisms. Protein and transcriptional analysis of livers revealed that activation of tumor necrosis factor superfamily members occurred by day 4 postexposure, implicating these molecules as factors in liver cell death. These data provide insights into CCHFV-induced hepatic injury and demonstrate the utility of antibody-mediated IFN-I blockade in the study of CCHFV pathogenesis in mice.IMPORTANCE CCHFV is an important human pathogen that is both endemic and emerging throughout Asia, Africa, and Europe. A common feature of acute disease is liver injury ranging from mild to fulminant hepatic failure. The processes through which CCHFV induces severe liver injury are unclear, mostly due to the limitations of existing small-animal systems. The only small-animal model in which CCHFV consistently produces severe liver damage is mice lacking IFN-I signaling. In this study, we used antibody-mediated blockade of IFN-I signaling in mice to study CCHFV liver pathogenesis in various transgenic mouse systems. We found that liver injury did not depend on cytotoxic immune cells and observed extensive activation of death receptor signaling pathways in the liver during acute disease. Furthermore, acute CCHFV infection resulted in a nearly complete loss of Kupffer cells. Our model system provides insight into both the molecular and the cellular features of CCHFV hepatic injury.

Entities:  

Keywords:  Crimean-Congo hemorrhagic fever virus; Kupffer cells; Nairoviridae; death receptor signaling; hepatic injury; pathogenesis

Mesh:

Substances:

Year:  2018        PMID: 30111561      PMCID: PMC6189508          DOI: 10.1128/JVI.01083-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

1.  Experimental infection of ostriches with Crimean-Congo haemorrhagic fever virus.

Authors:  R Swanepoel; P A Leman; F J Burt; J Jardine; D J Verwoerd; I Capua; G K Brückner; W P Burger
Journal:  Epidemiol Infect       Date:  1998-10       Impact factor: 2.451

2.  Identification of broadly neutralizing monoclonal antibodies against Crimean-Congo hemorrhagic fever virus.

Authors:  Marko Zivcec; Lisa I W Guerrero; César G Albariño; Éric Bergeron; Stuart T Nichol; Christina F Spiropoulou
Journal:  Antiviral Res       Date:  2017-08-24       Impact factor: 5.970

Review 3.  Role of Kupffer cells in host defense and liver disease.

Authors:  Manfred Bilzer; Frigga Roggel; Alexander L Gerbes
Journal:  Liver Int       Date:  2006-12       Impact factor: 5.828

4.  Blockade of chronic type I interferon signaling to control persistent LCMV infection.

Authors:  Elizabeth B Wilson; Douglas H Yamada; Heidi Elsaesser; Jonathan Herskovitz; Jane Deng; Genhong Cheng; Bruce J Aronow; Christopher L Karp; David G Brooks
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

5.  Is there any relationship between Toll-like receptor 3 c.1377C/T and -7C/A polymorphisms and susceptibility to Crimean Congo hemorrhagic fever?

Authors:  Aynur Engin; Serdal Arslan; Nil Özbilüm; Mehmet Bakir
Journal:  J Med Virol       Date:  2016-03-18       Impact factor: 2.327

6.  Viremia and antibody response of small African and laboratory animals to Crimean-Congo hemorrhagic fever virus infection.

Authors:  A J Shepherd; P A Leman; R Swanepoel
Journal:  Am J Trop Med Hyg       Date:  1989-05       Impact factor: 2.345

Review 7.  Death receptor activation-induced hepatocyte apoptosis and liver injury.

Authors:  Xiao-Ming Yin; Wen-Xing Ding
Journal:  Curr Mol Med       Date:  2003-09       Impact factor: 2.222

8.  MARCO, TLR2, and CD14 are required for macrophage cytokine responses to mycobacterial trehalose dimycolate and Mycobacterium tuberculosis.

Authors:  Dawn M E Bowdish; Kaori Sakamoto; Mi-Jeong Kim; Mariliis Kroos; Subhankar Mukhopadhyay; Cynthia A Leifer; Karl Tryggvason; Siamon Gordon; David G Russell
Journal:  PLoS Pathog       Date:  2009-06-12       Impact factor: 6.823

9.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

Review 10.  Crimean-Congo haemorrhagic fever.

Authors:  Onder Ergönül
Journal:  Lancet Infect Dis       Date:  2006-04       Impact factor: 25.071

View more
  15 in total

1.  Crimean-Congo Hemorrhagic Fever Mouse Model Recapitulating Human Convalescence.

Authors:  David W Hawman; Kimberly Meade-White; Elaine Haddock; Rumi Habib; Dana Scott; Tina Thomas; Rebecca Rosenke; Heinz Feldmann
Journal:  J Virol       Date:  2019-08-28       Impact factor: 5.103

Review 2.  Immunobiology of Crimean-Congo hemorrhagic fever.

Authors:  Sergio E Rodriguez; David W Hawman; Teresa E Sorvillo; T Justin O'Neal; Brian H Bird; Luis L Rodriguez; Éric Bergeron; Stuart T Nichol; Joel M Montgomery; Christina F Spiropoulou; Jessica R Spengler
Journal:  Antiviral Res       Date:  2022-01-11       Impact factor: 10.103

3.  Differential Growth Characteristics of Crimean-Congo Hemorrhagic Fever Virus in Kidney Cells of Human and Bovine Origin.

Authors:  Katalin Földes; Touraj Aligholipour Farzani; Koray Ergünay; Aykut Ozkul
Journal:  Viruses       Date:  2020-06-25       Impact factor: 5.048

Review 4.  Recent advances in understanding Crimean-Congo hemorrhagic fever virus.

Authors:  David W Hawman; Heinz Feldmann
Journal:  F1000Res       Date:  2018-10-29

5.  GP38-targeting monoclonal antibodies protect adult mice against lethal Crimean-Congo hemorrhagic fever virus infection.

Authors:  Joseph W Golden; Charles J Shoemaker; Michael E Lindquist; Xiankun Zeng; Sharon P Daye; Janice A Williams; Jun Liu; Kayla M Coffin; Scott Olschner; Olivier Flusin; Louis A Altamura; Kathleen A Kuehl; Collin J Fitzpatrick; Connie S Schmaljohn; Aura R Garrison
Journal:  Sci Adv       Date:  2019-07-10       Impact factor: 14.136

Review 6.  Animal Models for Crimean-Congo Hemorrhagic Fever Human Disease.

Authors:  Aura R Garrison; Darci R Smith; Joseph W Golden
Journal:  Viruses       Date:  2019-06-28       Impact factor: 5.048

Review 7.  The Integration of Human and Veterinary Studies for Better Understanding and Management of Crimean-Congo Haemorrhagic Fever.

Authors:  Ciaran Gilbride; Jack Saunders; Hannah Sharpe; Emmanuel Atangana Maze; Georgina Limon; Anna Barbara Ludi; Teresa Lambe; Sandra Belij-Rammerstorfer
Journal:  Front Immunol       Date:  2021-03-18       Impact factor: 7.561

8.  Characterization of a novel STAT 2 knock-out hamster model of Crimean-Congo hemorrhagic fever virus pathogenesis.

Authors:  Charlene Ranadheera; Emelissa J Valcourt; Bryce M Warner; Guillaume Poliquin; Kyle Rosenke; Kathy Frost; Kevin Tierney; Greg Saturday; Jinxin Miao; Jonna B Westover; Brian B Gowen; Stephanie Booth; Heinz Feldmann; Zhongde Wang; David Safronetz
Journal:  Sci Rep       Date:  2020-07-23       Impact factor: 4.996

Review 9.  The Utility of Human Immune System Mice for High-Containment Viral Hemorrhagic Fever Research.

Authors:  David M Wozniak; Kerry J Lavender; Joseph Prescott; Jessica R Spengler
Journal:  Vaccines (Basel)       Date:  2020-02-22

10.  Fluorescent Crimean-Congo hemorrhagic fever virus illuminates tissue tropism patterns and identifies early mononuclear phagocytic cell targets in Ifnar-/- mice.

Authors:  Stephen R Welch; Jana M Ritter; Anita K McElroy; Jessica R Harmon; JoAnn D Coleman-McCray; Florine E M Scholte; Gary P Kobinger; Éric Bergeron; Sherif R Zaki; Stuart T Nichol; Jessica R Spengler; Christina F Spiropoulou
Journal:  PLoS Pathog       Date:  2019-12-02       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.